Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

被引：16
|
作者：
Zhou, Jichun [1 ]
Teng, Rongyue [1 ]
Wang, Qinchuan [1 ]
Xu, Chenpu [1 ]
Guo, Jufeng [1 ]
Yuan, Chao [1 ]
Shen, Jianguo [1 ]
Hu, Wenxian [1 ]
Wang, Linbo [1 ]
Xie, Shuduo [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310016, Zhejiang, Peoples R China
来源：
ONCOLOGY LETTERS | 2013年 / 6卷 / 02期
基金：
中国国家自然科学基金;
关键词：
miRNAs; breast cancer; endocrine resistance; ESTROGEN-RECEPTOR-ALPHA; MICRORNA EXPRESSION; POSTMENOPAUSAL WOMEN; GENE-EXPRESSION; TAMOXIFEN RESISTANCE; AROMATASE INHIBITORS; DOWN-REGULATION; TUMOR INVASION; SMALL RNAS; THERAPY;
D O I：
10.3892/ol.2013.1405
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Current endocrine therapies for females with estrogen receptor-positive breast cancer have facilitated substantial improvements in outcomes. The effectiveness of endocrine therapy is limited by either initial de novo resistance or acquired endocrine resistance. Multiple mechanisms responsible for endocrine resistance have been proposed, including deregulation of various components of the estrogen receptor (ER) pathway, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways. Dysregulation of miRNA expression has been associated with experimental and clinical endocrine therapy resistance. miRNAs are pivotal to understanding the complex biological mechanism of endocrine resistance, and may serve as novel candidate predictive and prognostic surrogates and therapeutic targets. This review focuses on current progress concerning the roles of miRNAs in endocrine resistance, and discusses the challenges and opportunities for implementing miRNA-based assays and treatment for patients with endocrine-resistant breast cancer.
引用
收藏
页码：295 / 305
页数：11
相关论文
共 50 条
  • [31] Functional miRNAs in breast cancer drug resistance
    Hu, Weizi
    Tan, Chunli
    He, Yunjie
    Zhang, Guangqin
    Xu, Yong
    Tang, Jinhai
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 1529 - 1541
  • [32] Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
    Irene E. G. van Hellemond
    Sandra M. E. Geurts
    Vivianne C. G. Tjan-Heijnen
    [J]. Current Treatment Options in Oncology, 2018, 19
  • [33] Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
    van Hellemond, Irene E. G.
    Geurts, Sandra M. E.
    Tjan-Heijnen, Vivianne C. G.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
  • [34] The role of miRNAs in tamoxifen resistance in breast cancer
    Healy, N. A.
    Schiff, R.
    Miller, N.
    Osborne, C. K.
    Kerin, M. J.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 : 8 - 8
  • [35] Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
    Milani, Andrea
    Geuna, Elena
    Mittica, Gloria
    Valabrega, Giorgio
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (05): : 990 - 1001
  • [36] Mechanisms of Endocrine Resistance in Breast Cancer
    Osborne, C. Kent
    Schiff, Rachel
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 : 233 - 247
  • [37] Overcoming Endocrine Resistance in Breast Cancer
    Madaio, R. A.
    Spalletta, G.
    Cravello, L.
    Ceci, M.
    Repetto, L.
    Naso, G.
    [J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (05) : 519 - 528
  • [38] Endocrine resistance in advanced breast cancer
    Dowsett, M
    [J]. ACTA ONCOLOGICA, 1996, 35 (05) : 91 - 95
  • [39] Resistance to endocrine therapy in breast cancer
    Kurebayashi, J
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (Suppl 1) : S39 - S46
  • [40] Acquired endocrine resistance in breast cancer
    [J]. Nature Reviews Endocrinology, 2014, 10 (2) : 66 - 66
12345